For years, lawmakers have targeted the pharmaceutical industry, blaming it for the high cost of healthcare – its role in the management of Covid-19 notwithstanding. Despite recent breakthroughs to rid the world of its worst scourges, both the U.S. and EU appear to regard pharma as the single worst actor…
Pharmaceutical executives are waking up to a hard new reality. The winds of healthcare economic change, accelerated by a historic pandemic, have upended the old “feet on the street” commercial sales playbook by which they successfully operated for good. Whether pharma leaders like it or not, the future of the…
For years, lawmakers have been chomping at the bit to reduce the perceived power of the pharmaceutical industry — once the crown jewel of American business. Their efforts have finally come to fruition with the signing into law of the misnamed Inflation Reduction Act. The law, in part, allows Medicare…
Among the many trends accelerated by the pandemic was the overhaul of pharma’s commercial model. It was tacitly understood to be ripe for change – the cost was increasingly conspicuous, and the results increasingly suspect. The prior model had grown out of step with field realities. Employed physicians had less…
